Niopam (Iopamidol)

Iopamidol provides radiopacity by delivering a high concentration of iodine atoms that absorb X‑ray photons. After injection, it distributes in the vascular and interstitial spaces, creating a temporary window of increased radiodensity that outlines anatomical structures, allowing clinicians to differentiate normal from pathological tissues on imaging studies.

The dose of Niopam is determined by the prescribing physician based on the specific imaging study, patient weight, renal function and the required level of contrast enhancement. The healthcare professional selects the appropriate volume and concentration to achieve optimal image quality while minimizing exposure.

The safety of iopamidol‑containing contrast agents in pregnancy and lactation has not been definitively established. Use is generally reserved for situations where the diagnostic benefit outweighs potential risk, and the decision should be made by the treating physician in consultation with obstetric specialists.

To place an order, submit an enquiry on the Niopam product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Niopam (iopamidol) is a non‑ionic, low‑osmolar contrast medium, which typically offers a lower incidence of adverse reactions compared with older high‑osmolar agents. Its iodine concentration provides comparable image quality to other low‑osmolar agents such as iohexol, while its safety profile is favorable for patients with moderate renal risk.

Niopam should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze or shake the vial before use; inspect for particulate matter or discoloration prior to administration.

Niopam is supplied as a sterile solution for injection and is administered intravenously or intra‑arterially by a qualified healthcare professional. The injection is typically performed using a power injector or manual bolus, following aseptic technique and appropriate dosing calculations for the intended imaging study.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal failure, and cardiovascular events like profound hypotension or arrhythmias. Prompt recognition and emergency management are essential if these reactions occur during or after administration.

Niopam is contraindicated in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, as well as in individuals with uncontrolled severe renal impairment where the risk of contrast‑induced nephropathy outweighs diagnostic benefit. Clinicians should also exercise caution in patients with uncontrolled thyroid disease or a history of severe allergic reactions.